Characteristic,Percentage of drugs approved in 2019
Met PDUFA goal date*,100%
First cycle of review,92%
Approved in the United States before receiving approval in any other country,75%
Drugs for orphan diseases,58%
Priority review,57%
Breakthrough therapy,42%
First-in-class,40%
Fast Track,32%
Accelerated Approval program,23%
